US Bancorp
CLVS

US Bancorp’s Clovis Oncology, Inc. CLVS Stock Holding History

US Bancorp’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,687
Closed -$23K – 4331
2022
Q3 		$23K Hold
19,687
– – ﹤0.01% 2973
2022
Q2 		$36K Sell
19,687
-2,192
-10% -$3.23K ﹤0.01% 2774
2022
Q1 		$44K Buy
21,879
+466
+2% +$915 ﹤0.01% 2698
2021
Q4 		$59K Sell
21,413
-1,484
-6% -$5.49K ﹤0.01% 2565
2021
Q3 		$103K Buy
22,897
+3,026
+15% +$14.6K ﹤0.01% 2292
2021
Q2 		$115K Sell
19,871
-512
-3% -$3K ﹤0.01% 2236
2021
Q1 		$143K Sell
20,383
-8,100
-28% -$54.3K ﹤0.01% 2077
2020
Q4 		$137K Buy
28,483
+5,580
+24% +$28.2K ﹤0.01% 2052
2020
Q3 		$133K Sell
22,903
-2,198
-9% -$13.2K ﹤0.01% 1954
2020
Q2 		$170K Buy
25,101
+402
+2% +$3.04K ﹤0.01% 1847
2020
Q1 		$157K Buy
24,699
+199
+0.8% +$1.6K ﹤0.01% 1787
2019
Q4 		$256K Buy
24,500
+19,500
+390% +$142K ﹤0.01% 1709
2019
Q3 		$20K Sell
5,000
-5,991
-55% -$48.5K ﹤0.01% 2853
2019
Q2 		$164K Buy
10,991
+2,171
+25% +$39.2K ﹤0.01% 1927
2019
Q1 		$219K Buy
8,820
+681
+8% +$17.1K ﹤0.01% 1769
2018
Q4 		$146K Buy
8,139
+2,075
+34% +$42.4K ﹤0.01% 1922
2018
Q3 		$178K Buy
6,064
+709
+13% +$27.4K ﹤0.01% 1929
2018
Q2 		$243K Sell
5,355
-234
-4% -$11.4K ﹤0.01% 1774
2018
Q1 		$296K Buy
5,589
+4,981
+819% +$291K ﹤0.01% 1671
2017
Q4 		$41K Buy
608
+195
+47% +$13.6K ﹤0.01% 2689
2017
Q3 		$34K Buy
413
+319
+339% +$25.3K ﹤0.01% 2724
2017
Q2 		$8K Buy
94
+33
+54% +$2.02K ﹤0.01% 3121
2017
Q1 		$4K Buy
+61
New +$3.71K ﹤0.01% 3283
2016
Q1 		– Sell
-1,059
Closed -$37K – 3696
2015
Q4 		$37K Buy
1,059
+289
+38% +$18.6K ﹤0.01% 2585
2015
Q3 		$71K Sell
770
-764
-50% -$66.1K ﹤0.01% 2278
2015
Q2 		$134K Buy
1,534
+66
+4% +$5.65K ﹤0.01% 1971
2015
Q1 		$109K Buy
1,468
+92
+7% +$6.5K ﹤0.01% 2121
2014
Q4 		$77K Buy
1,376
+393
+40% +$20.7K ﹤0.01% 2304
2014
Q3 		$45K Buy
+983
New +$41.1K ﹤0.01% 2543

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

US Bancorp's CLVS Position: Q4 2022 in Review

US Bancorp sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 19,687 shares — an estimated $23K sold.

US Bancorp first reported a position in CLVS in Q3 2014 and held it in 29 quarters. The position peaked at $296K in Q1 2018. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • US Bancorp reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • US Bancorp sold 19,687 Clovis Oncology, Inc. shares in Q4 2022, an estimated $23K.
  • US Bancorp first reported a position in Clovis Oncology, Inc. in Q3 2014 and held it in 29 quarters.
  • US Bancorp's Clovis Oncology, Inc. position peaked at $296K in Q1 2018.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on US Bancorp's 13F filing for Q4 2022, filed 13 Feb 2023.